Novartis lifts sales growth target to 5% per year through 2027

The medium-term target is mainly driven by six drugs, led by a breast cancer drug

Last month, the Basel-based drugmaker spun off and listed generic drugs business Sandoz and raised its 2023 earnings forecast for the third time. Picture: Jim Coughlan.

Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business.

The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday.